Trial · NCT03701555
Participant flow648
How many started, completed or left each group, period by period.
1 to 20 of 648
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1 (Day 1) | STARTED | Part 1, (1A-1): PvP001 Placebo | 3 | |
| Part 1 (Day 1) | STARTED | Part 1, (1B-1): PvP001 100 mg | 3 | |
| Part 1 (Day 1) | STARTED | Part 1, (1C-1): PvP001 300 mg | 3 | |
| Part 1 (Day 1) | STARTED | Part 1, (1D-1): PvP001 900 mg | 3 | |
| Part 1 (Day 1) | STARTED | Part 1, (1E-1): PvP002 600 mg | 3 | |
| Part 1 (Day 1) | STARTED | Part 1, (1A-2): PvP001 Placebo | 3 | |
| Part 1 (Day 1) | STARTED | Part 1, (1B-2): PvP001 100 mg | 3 | |
| Part 1 (Day 1) | STARTED | Part 1, (1C-2): PvP001 300 mg | 3 | |
| Part 1 (Day 1) | STARTED | Part 1, (1D-2): PvP001 900 mg | 3 | |
| Part 1 (Day 1) | STARTED | Part 1, (1E-2): PvP002 600 mg | 1 | |
| Part 1 (Day 1) | STARTED | Part 2, Group 1: PvP001 Placebo (2A) + PvP001 900 mg (2B) + PvP001 900 mg With PPI (2C) | 0 | |
| Part 1 (Day 1) | STARTED | Part 2, Group 1: PvP001 Placebo (2A) + PvP001 900 mg With PPI (2C) + PvP001 900 mg (2B) | 0 | |
| Part 1 (Day 1) | STARTED | Part 2, Group 1: PvP001 900 mg (2B) + PvP001 Placebo (2A) + PvP001 900 mg With PPI (2C) | 0 | |
| Part 1 (Day 1) | STARTED | Part 2, Group 1: PvP001 900 mg (2B) + PvP001 900 mg With PPI (2C) + PvP001 Placebo (2A) | 0 | |
| Part 1 (Day 1) | STARTED | Part 2, Group 1: PvP001 900 mg With PPI (2C) + PvP001 Placebo (2A) + PvP001 900 mg (2B) | 0 | |
| Part 1 (Day 1) | STARTED | Part 2, Group 1: PvP001 900 mg With PPI (2C) + PvP001 900 mg (2B) + PvP001 Placebo (2A) | 0 | |
| Part 1 (Day 1) | STARTED | Part 2, Group 2: PvP002 Comparator (2D) + PvP002 600 mg (2E) | 0 | |
| Part 1 (Day 1) | STARTED | Part 2, Group 2: PvP002 600 mg (2E) + PvP002 Comparator (2D) | 0 | |
| Part 1 (Day 1) | STARTED | Part 2, Group 3: PvP001 Placebo (2F) + PvP001 300 mg (2G) | 0 | |
| Part 1 (Day 1) | STARTED | Part 2, Group 3: PvP001 300 mg (2G) + PvP001 Placebo (2F) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03701555/flow